Abstract:In effort s to achieve minimal systemic toxicity and high tumor delivery efficiencies in cancer therapy, various nanomedicine formulations having stealth polymer coatings have been developed for minimizing immune cell uptake and off-target macrophage phagocyte system (MPS) organ accumulation. Despite an initial reduction in immune cell uptake, stealth nanoparticles still initiate an antibody immune response. This response acts on subsequent administrations in treatment regimens resulting in accelerated blood clearance of particles into MPS organs, particularly the liver, where they are retained for prolonged periods. Consequently, doses after the first administration in treatment regimens have diminished tumor accumulation and increased MPS toxicity. Here, we present a strategy reducing antibody responses to each dose in a treatment regimen by alternating between polyethylene-glycol and polymethyloxazoline polymers as the nanoparticle coating between administrations. In a weekly dosing regimen, we find that the first dose of particles having either coating display similar favorable pharmacokinetics and biodistributions, thus allowing the polymers to be used interchangeably. However, when maintaining the same coating in subsequent administrations, we find that particles are in circulation at the height of the antibody immune response resulting in 50-60% decreases of circulation half-lives and tumor accumulation along with 50% increases in liver accumulation. By alternating the polymers used in the nanoparticle coating between administrations, we find each dose maintains favorable in vivo behaviors at the height of the antibody immune response to the previous administration. Furthermore, our strategy increases the clearance of particles uptaken by macrophages and hepatocytes, resulting in marked decreases in hepatotoxicity. Statement of significance While nanoparticles with coatings consisting of stealth polymers can minimize immune cell uptake, they still initiate antibody immune responses leading to rapid blood clearance and MPS sequestration of subsequent administrations within a treatment regimen. We demonstrate that by alternating PEG and PMOZ polymer coatings between weekly administrations, the antibody immune response acting on each administration is minimal, and the favorable in vivo behaviors observed with the first administration is maintained in subsequent administrations. In this case, greater tumor accumulation is achieved while curtailing excessive MPS organ accumulation and toxicity throughout a nanomedicine treatment. We envision our strategy will benefit clinical trials where frequent administrations of therapeutics are required or in sequential deliveries of prognostic and therapeutic agents. (c) 2021 Published by Elsevier Ltd on behalf of Acta Materialia Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/)

Zwitterionic stealth peptide-protected gold nanoparticles enable long circulation without the accelerated blood clearance phenomenon.

Engineering Poly(ethylene Glycol) Nanoparticles for Accelerated Blood Clearance Inhibition and Targeted Drug Delivery.

PEGylation and Zwitterionization: Pros and Cons in the Renal Clearance and Tumor Targeting of Near-Ir-emitting Gold Nanoparticles.

Mixed-charge nanoparticles for long circulation, low reticuloendothelial system clearance, and high tumor accumulation.

Minimizing Nonspecific Phagocytic Uptake of Biocompatible Gold Nanoparticles with Mixed Charged Zwitterionic Surface Modification

Evasion of the accelerated blood clearance phenomenon by branched PEG lipid derivative coating of nanoemulsions

The enhancement effect of gold nanoparticles in drug delivery and as biomarkers of drug-resistant cancer cells.

Tumor microenvironment-responsive multifunctional peptide coated ultrasmall gold nanoparticles and their application in cancer radiotherapy.

Size- and surface chemistry-dependent pharmacokinetics and tumor accumulation of engineered gold nanoparticles after intravenous administration.

Pharmacokinetics, Clearance, and Biosafety of Polyethylene Glycol-Coated Hollow Gold Nanospheres

Poly(carboxybetaine) Nanomaterials Enable Long Circulation and Prevent Polymer-Specific Antibody Production

Ultra-Small Gold Nanoparticles Behavior in Vivo Modulated by Surface PEG Grafting.

Accelerated blood clearance of PEGylated nanoparticles induced by PEG-based pharmaceutical excipients

Cross-Linked Polyethylene Glycol Shells for Nanoparticles: Enhanced Stealth Effect and Colloidal Stability.

Gold nanoparticles stabilize peptide-drug-conjugates for sustained targeted drug delivery to cancer cells

Ultrastable Polyethyleneimine-Stabilized Gold Nanoparticles Modified with Polyethylene Glycol for Blood Pool, Lymph Node and Tumor Ct Imaging

Multiscale Synchrotron-Based Imaging Analysis for the Transfer of PEGylated Gold Nanoparticles in Vivo.

The biological response of pH-switch-based gold nanoparticle-composite polyamino acid embolic material

Alternating Stealth Polymer Coatings Between Administrations Minimizes Toxic and Antibody Immune Responses Towards Nanomedicine Treatment Regimens.

Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy

Dose Dependencies and Biocompatibility of Renal Clearable Gold Nanoparticles.